Wyeth Declares Preferred Stock Dividend ( MADISON N.J. Nov. 20 /- At a meeting ...)

Wyeth Declares Preferred Stock Dividend

Date:11/20/2008

MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- At a meeting of the Board of Directors of Wyeth (NYSE: WYE), held today, a dividend of fifty cents($0.50) per share on the outstanding shares of Preferred Stock was declared payable on January 2, 2009 to stockholders of record at the close of business on December 12, 2008.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/5/2013)... 2013 MO BIO Laboratories, Inc., the leader ... purification, has been independently audited and is now ... of reagents and kits for extraction, purification and ... community, along with providing 3rd party independent laboratory ... (Photo: http://photos.prnewswire.com/prnh/20131205/LA27735 ) ...

(Date:12/5/2013)... CA (PRWEB) December 05, 2013 ... invites senior industry executives, domain experts, technologists and ... research initiative studying the “Mesenchymal Stem Cells (MSCs)” ... trends impacting the market such as increased investments ... in the number of patent applications in the ...

(Date:12/5/2013)... Ga. , Dec. 5, 2013 MiMedx Group, ... developer, manufacturer and marketer of patent protected regenerative ... provided an update yesterday on its continuing discussions ... the regulatory classification of its micronized products. In ... its support of the new CMS Skin Substitute ...

(Date:12/5/2013)... The integration of genomics into the ... development in cancer. The first iteration was characterized by ... A second wave of change came with development of ... such as Herceptin® for the over-expression of HER2. Today, ... alterations has led to a need to more fully ...

Breaking Biology Technology:MO BIO Laboratories, Inc. becomes ISO 9001:2008 certified 2 Growing Interest in Regenerative Medicine to Drive the Mesenchymal Stem Cells Market, According to a Soon to Be Released Report by Global Industry Analysts, Inc. 2 Growing Interest in Regenerative Medicine to Drive the Mesenchymal Stem Cells Market, According to a Soon to Be Released Report by Global Industry Analysts, Inc. 3 MiMedx Schedules Conference Call To Discuss Impact Of CMS Policy And Ongoing FDA Discussions 2 Catching up with the Genomic Era in Oncology: Key Considerations for Incorporating Genomics into Oncology Drug Development, a New and Upcoming Webinar Hosted by Xtalks 2

[0] MO BIO Laboratories, Inc. becomes ISO 9001:2008 certified [0] Growing Interest in Regenerative Medicine to Drive the Mesenchymal Stem Cells Market, According to a Soon to Be Released Report by Global Industry Analysts, Inc.[0] MiMedx Schedules Conference Call To Discuss Impact Of CMS Policy And Ongoing FDA Discussions [0] Catching up with the Genomic Era in Oncology: Key Considerations for Incorporating Genomics into Oncology Drug Development, a New and Upcoming Webinar Hosted by Xtalks

... - Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the ... ended December 31, 2007., "2007 was our ... of the Company,s clinical trial program for REOLYSIN(R) ... being expanded and,initiated," said Dr. Brad Thompson, President ...

... March 6 VWR Funding, Inc., the,parent company of VWR International, LLC, a leading global ... and year-end financial results., Who: ... Jack L. Wyszomierski, Executive Vice-President & Chief ... Financial Officer, When: Wednesday, March 12, ...

... on Clinical Developments, MONTREAL, March 6 /PRNewswire-FirstCall/ - ... findings from the,third cohort in its Phase II trial ... the compiled data from a,total of 18 patients showed ... at weeks 4, 6 and 8, and of the ...

Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 VWR Funding, Inc. to Hold Fourth Quarter and Year-End 2007 Financial Results Conference Call ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia

(Date:12/5/2013)... over a million people with spinal cord injuries (SCI) ... new cases every year. Furthermore, it is estimated that ... the VA the largest integrated health care system in ... prevalence, researchers are still discovering all the various ways ... obvious paralysis. For example, researchers have long known that ...

(Date:12/5/2013)... for the first time in mammalian brain cells, researchers ... involved in building the circuitry that relays signals through ... the aging process in the brain, the researchers say. ... the discovery paves the way for faster progress toward ... autism and schizophrenia as well as potential drugs ...

(Date:12/5/2013)... simple mechanical model to effectively implement the well-known double-stranded ... scale has been developed by Jae-Hyung Jeon and Wokyung ... the Republic of Korea, in an effort to more ... cells. The model was published in Springer,s Journal ... and Crick first described the basic structure of DNA ...

Breaking Biology News(10 mins):Quadriplegics at risk for serious sleep breathing disorder 2 Quadriplegics at risk for serious sleep breathing disorder 3 Gene found to be crucial for formation of certain brain circuitry 2 DNA helicity and elasticity explained on the nanoscale 2

[0] Quadriplegics at risk for serious sleep breathing disorder [0] Gene found to be crucial for formation of certain brain circuitry [0] DNA helicity and elasticity explained on the nanoscale

... and diesel with plant-based bio fuels is crucial to curb climate ... and some of the methods result in bio fuels that are ... from the University of Copenhagen shows that it is possible to ... single drop. This promises cheaper, faster and above all safer development ...

... usually progresses in small steps, but on rare occasions, ... produces a ,great leap forward., An international team of ... Joseph Ecker, report one such leap in the July ... their mapping and early analyses of thousands of protein-to-protein ...

... 29, 2011Intravenous delivery of cold fluids to reduce body ... outcomes may not be as effective in children as ... in Therapeutic Hypothermia and Temperature Management , a ... article is available free online at www.liebertpub.com/ther ...

Cached Biology News:Computational chemistry shows the way to safer biofuels 2 Scientists take a giant step for people -- with plants! 2 Scientists take a giant step for people -- with plants! 3 Scientists take a giant step for people -- with plants! 4

Computational chemistry shows the way to safer biofuels Scientists take a giant step for people -- with plants!New findings on therapeutic hypothermia following cardiac arrest in children

... the principal excitatory neurotransmitter receptors ... glutamate receptors exist: Ionotropic receptors, ... receptors are oligomeric complexes of ... which comprise ligand-gated calcium channels. ...

Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...

... corresponds to amino acids 2-105 from human ... successfully used in Western blot, immunocytochemistry and ... antibody detects an ~ 60 kDa protein ... been used in immunoprecipitation and immunocytochemical procedures. ...

... labware carriers to suit the widest possible ... life science laboratory. Labware carriers can be ... Mounting is simple for the user, thanks ... carriers are correctly guided into position. This ...

Biology Products:

Rabbit Anti-GluR4 Antibody, Unconjugated from Lab Vision Chicken Anti-Human Complement Component C4c Antibody, Unconjugated from CEDARLANE Laboratories Limited Rabbit Anti-SKAP55 Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents Labware Carriers from Tecan